Axsome Therapeutics Inc (AXSM)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

22 CORTLANDT STREET, 16TH FLOOR NEW YORK, NY 10007

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.

Data as of 2021-08-02 08:47:33 -0400
Market Cap1.826 Billion Shares Outstanding37.57 Million Avg 30-day Volume360.324 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.34 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.10113 52-week High/Low90.0 / 48.34 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -86.2501
Data provided by IEX Cloud
View SEC Filings from AXSM instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 3 4 -25.0% 3 (0.18%) 4 (0.23%) -25.0%
Funds Holding: 180 178 1.12% 56 (3.29%) 60 (3.48%) -6.67%
13F shares: 22.759 Million 23.916 Million -4.84% 11.971 Million 11.891 Million 0.68%
% Ownership 60.844 64.0425 -4.99% 32.0041 31.8414 0.51%
New Positions: 33 23 43.48% 7 10 -30.0%
Increased Positions 63 66 -4.55% 19 25 -24.0%
Closed Positions 29 17 70.59% 11 6 83.33%
Reduced Positions 51 58 -12.07% 20 16 25.0%
Total Calls 243.587 Thousand 633.548 Thousand -61.55% 122.5 Thousand 186 Thousand -34.14%
Total Puts 950.13 Thousand 690.245 Thousand 37.65% 305.5 Thousand 201.4 Thousand 51.69%
PUT/CALL Ratio 3.9 1.09 257.8% 2.49 1.08 130.56%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AXSM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AXSM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COLEMAN MARK

  • Director
7,325 2021-06-04 4

JEFFS ROGER

  • Director
7,325 2021-06-04 2

SAAD MARK E

  • Director
7,325 2021-06-04 2

TABUTEAU HERRIOT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
148,870 2021-03-05 1

PIZZIE NICK CHIEF FINANCIAL OFFICER

  • Officer
55,294 2021-03-05 1

JACOBSON MARK L. CHIEF OPERATING OFFICER

  • Officer
63,801 2021-03-05 1

MAREK DAVID C CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-03-17 0

POTTER MYRTLE S

  • Director
0 2019-06-07 0

GOLUBIESKI JOHN CHIEF FINANCIAL OFFICER

  • Officer
0 2017-08-04 0

AMES CONSTANCE VICE PRESIDENT, FINANCE

  • Officer
0 2017-03-15 0

KAYE RANDALL CHIEF MEDICAL OFFICER

  • Officer
6,022 2015-12-23 0

ANTECIP CAPITAL LLC

  • 10% Owner
7,344,500 2015-11-19 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

COLEMAN MARK - Director

2021-06-08 16:51:49 -0400 2021-06-04 A 7,325 a 7,325 direct

SAAD MARK E - Director

2021-06-08 16:52:53 -0400 2021-06-04 A 7,325 a 7,325 direct

JEFFS ROGER - Director

2021-06-08 16:52:13 -0400 2021-06-04 A 7,325 a 7,325 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AXSOME THERAPEUTICS INC AXSM 2021-08-02 22:15:03 UTC -0.2053 0.2653 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 21:45:03 UTC -0.2053 0.2653 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 21:15:03 UTC -0.2053 0.2653 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 20:45:03 UTC -0.2559 0.3159 950000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 20:15:03 UTC -0.2559 0.3159 950000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 19:45:03 UTC -0.2559 0.3159 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 19:15:03 UTC -0.2559 0.3159 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 18:45:03 UTC -0.4083 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 18:15:03 UTC -0.4083 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 17:45:03 UTC -0.4083 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 17:15:03 UTC -0.4083 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 16:45:03 UTC -0.3883 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 16:15:03 UTC -0.3883 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 15:45:03 UTC -0.3883 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 15:15:03 UTC -0.3883 0.4683 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 14:45:03 UTC -0.1905 0.2705 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 14:15:03 UTC -0.1905 0.2705 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 13:45:03 UTC -0.1905 0.2705 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 13:15:04 UTC -0.1905 0.2705 1000000
AXSOME THERAPEUTICS INC AXSM 2021-08-02 12:45:03 UTC -0.1905 0.2705 1000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund AXSM -34.0 shares, $-2000.22 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund AXSM -22.0 shares, $-1294.26 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund AXSM -38.0 shares, $-2235.54 2020-03-31 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund AXSM -607.0 shares, $-36850.97 2021-05-31 N-PORT

Elevate your investments